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reveals not only an array of membrane 
proteins from the apical endosomal path-
way of multiple cell types but a variety of 
entrained cytosolic proteins.5 Not sur-
prisingly, urinary exosomes also contain 
ALIX, ubiquitin, and all components of 
the ESCRT-I, ESCRT-II, and ESCRT-III 
complexes (our unpublished data). An 
interesting, important, and unanswered 
question is: What fraction of MVBs that 
form in renal epithelial cells are eliminated 
by this exocytic process versus the classical 
fate of late endosomes, namely, incorpo-
ration into lysosomes for degradation of 
their contents? Another important ques-
tion is: What are the mechanisms by which 
MVBs translocate to the apical region of 
epithelial cells and fuse with the plasma 
membrane? Finally, are there undiscov-
ered or unstudied disorders of exosome 
secretion that may shed light on their 
physiological roles, and are these abnor-
malities related to so-called disorders of 
lysosomal secretion such as Hermansky-
Pudlak syndrome, Griscelli syndrome, 
and Chediak-Higashi syndrome?
Regarding the presence of exosomes in 
urine, it is natural to ask the ‘why’ question: 
Why would evolution select for a process 
that generates and excretes exosomes, as 
opposed to disposing of cellular waste 
materials through degradative processes? 
One answer is the ‘1950s-theory-of-waste-
management’ approach, which consisted 
of getting rid of wastes by dumping them 
into the nearest ﬂowing stream. That is, it 
may be energetically eﬃcient to dispose of 
waste molecules by saving them in MVBs 
and translocating the contents periodi-
cally to the urinary space. Although this 
theory lends itself to graphic metaphors, 
it may not be the right answer. Exosomes 
are very small structures, each with a 
very small radius of curvature (Figure 
1a), which probably requires a signiﬁcant 
amount of energy for formation. There-
fore, it is not self-evident that excretion 
via exosomes is energy eﬃcient. Conse-
quently, it seems useful to look for other 
roles of exosomes beyond that of excretion 
of waste molecules. An intriguing idea was 
recently oﬀered in a paper by Valadi et al.10 
These authors demonstrated that, in addi-
tion to proteins, exosomes isolated from a 
number of cell types contain a variety of 
mRNA and microRNA molecules. It was 
proposed that exosomes provide a means 
by which neighboring cells can inﬂuence 
one another’s functions via transfer of 
these RNAs. This kind of model is of obvi-
ous interest in the area of developmental 
biology, where cell–cell interactions are 
critical for the orchestration of the diﬀer-
entiation of many tissues and cells in the 
appropriate sequence. Beyond this, if we 
assume that urinary exosomes also con-
tain speciﬁc mRNAs and microRNAs, it 
is conceivable that day-to-day regulation 
of nephron function could be mediated in 
part through a regulated process of exo-
some secretion and reuptake downstream 
in other cell types, where their component 
mRNA and microRNA molecules would 
alter the overall structure or function 
of the recipient cells. Such a possibility 
deserves examination.
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Measuring the burden of illness 
for end-stage renal disease: some 
heavy lifting required
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Estimates for the burden of illness (BOI) attributable to end-stage renal 
disease (ESRD) in Canada are presented in the article by Zelmer. This 
Commentary describes the methodology of BOI analysis, its role in 
formulating public policy, and the potential application to improving 
care for ESRD.
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People value good health, as does society 
overall. For the individual, illness and 
disability diminish the ability to function 
while increasing dependence on others. 
Pain and distress impede the enjoyment of 
life. For society, impaired population health 
reduces productivity and decreases gross 
domestic product. Treatment of disease 
and its broader impact necessitates diver-
sion of communal resources and increases 
tax burden. Individual suﬀering takes a toll 
on the national psyche.
Burden-of-illness (BOI) analysis involves 
methods for quantifying the societal 
impact of disease, disability, injury, and 
other forms of impaired health. Analysis of 
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cost of illness (COI), a component of BOI, 
assigns a monetary value to the toll of dis-
ease. Zelmer1 (this issue) reports estimates 
for the burden of end-stage renal disease 
(ESRD) in Canada.
Burden-of-illness analysis
Zelmer’s article1 raises several questions 
that this Commentary will address. How 
do analysts quantify and value something 
that manifests in so many diﬀerent ways 
and has such diverse and wide-ranging 
impact on human existence? Why conduct 
such analysis — how does it inform and 
shape public policy? Can this type of infor-
mation advance the care of ESRD?
BOI analysis examines the impact of 
impaired health from three perspectives 
that may be labeled epidemiology, cost of 
illness, and quality of life. Epidemiologic 
data describe the rate at which new cases 
appear (annual incidence) and the demo-
graphic characteristics of those aﬀected. 
Prevalence, the number of persons with the 
condition at a point in time, is determined 
by mortality, the annual death rate among 
those aﬀected. All these statistics can be 
reﬁned and cross-tabulated in numerous 
ways, such as by age group, sex, or stage 
of disease.
COI—the monetary impact of impaired 
health—is tabulated according to direct 
costs and indirect costs. Direct costs rep-
resent the value of resources that can be 
attributed to the treatment or care of a 
disease, such as hospital stays, physician 
services, pharmaceuticals, or transporta-
tion to a health-care facility. Ideally, these 
resources are valued at their true cost of 
production—the opportunity cost, in eco-
nomic terminology. In practice, analysts 
rely on billing records, health-insurance fee 
schedules, or facility internal accounting to 
establish market values for speciﬁc types of 
health services.
Indirect costs refer to the value of pro-
ductive economic activity that is lost as 
a consequence of a condition of interest. 
Lost productivity is typically valued by the 
‘human capital’ approach.2 Here the ﬁrst 
step is to deﬁne a cohort of persons with the 
condition and then calculate the number of 
lost or impaired productive years over their 
lifetimes. Next a value is assigned to each 
lost year on the basis of assumed wage rates. 
Controversy often arises in the valuation 
of productive years. Critics of the human 
capital approach argue that market wage 
rates undervalue the lives of groups such 
as minorities (because of depressed wages) 
or the elderly (who often are no longer in 
the work force). Zelmer’s estimate for the 
indirect costs of ESRD in Canada is highly 
sensitive to the valuation of unpaid labor.1
Quantifying the intangible impact of 
disease is especially challenging as there is 
no universal metric for quality of life. Most 
approaches combine data on the duration of 
a condition with a weighting factor on a 0–1 
scale that reﬂects the magnitude of deviation 
from an ideal state of being. For example, 
the quality-adjusted life year adjusts the 
time in a health state by patient preference 
for that health state. Preference weights are 
elicited by special-purpose questionnaires 
or exercises where respondents are oﬀered 
trade-oﬀs between alternative health states.3 
Critics view the quality-adjusted life year 
metric as subjective, diﬃcult to interpret, 
and lacking in cross-cultural generalizabil-
ity. As an alternative, economists working 
in developing nations devised the disabil-
ity-adjusted life year, which integrates func-
tional impairment, the degree to which the 
aﬀected individual can perform his or her 
normal activity, dependency, and expected 
survival.4
Role of burden-of-illness and cost-of- 
illness studies
The methodology of BOI is well developed, 
and a substantial literature exists describ-
ing the impact of numerous conditions. In 
general, the results of BOI analysis are used 
for one of two purposes: (1) to inﬂuence 
establishment of priorities for health-care 
expenditures; (2) as a component of cost-
eﬀectiveness or cost–beneﬁt analysis.
Cross-national comparisons of BOI 
describe the relative rankings of individ-
ual countries and can guide global devel-
opment eﬀorts. An example is the World 
Health Organization Global Burden of Dis-
ease project, which has tabulated mortal-
ity and disability for more than 100 major 
causes of death according to eight geo-
graphic regions and ten demographic cat-
egories.5 The burden of speciﬁc conditions 
within a nation can be quantiﬁed in terms 
of the overall magnitude of the condition 
or the per capita burden. A report from the 
National Cancer Institute gives estimates 
for total national expenditures and dis-
ability-adjusted life years for the most 
common types of cancer.6 BOI ﬁndings 
can call attention to unmet needs. Analy-
sis of a 1996 national health expenditure 
survey found that one-fourth of the United 
States population had one of ﬁve chronic 
conditions, which together accounted for 
more than $60 billion in direct and indirect 
costs. However, the most disabling condi-
tions did not account for commensurate 
medical expenditure.7,8
Just how useful BOI ﬁndings are for pri-
ority setting has been extensively debated 
in the literature.9,10 An example of the con-
troversy can be found in a report issued by 
the National Institutes of Health (NIH) in 
2000, which updated a similar 1995 report 
prompted by a Congressional inquiry.11 
The NIH compared BOI for 60 conditions 
studied by the various institutes relative to 
the research dollars allocated to each con-
dition. The political background for the 
report was concern on the part of main-
stream disease advocacy organizations 
that substantial funds were being diverted 
to new HIV/AIDS research programs. As 
the NIH explained to Congress, BOI has 
limited applicability for setting research 
priorities because of variability in meth-
ods and data, the diﬃculty of assigning 
cost to patients who have multiple chronic 
diseases, the importance of basic research 
that transcends speciﬁc diseases, and the 
importance of pursuing promising oppor-
tunities arising in particular ﬁelds.
Zelmer points to the value of BOI data 
as a metric for evaluating public-health 
programs.1 When acute conditions such 
as infectious disease were the focus of 
eﬀorts to improve public health, mortality 
and hospital-admission statistics provided 
a suﬃcient basis for measuring progress. 
However, in an era of chronic disease, in 
which patients may live with a condition 
for many years, BOI can serve as a mean-
ingful benchmark.
There is little controversy as to the role of 
BOI and COI in cost-eﬀectiveness analy-
sis.12 Cost-eﬀectiveness analysis compares 
alternative interventions on the basis of 
the ratio of the incremental change in out-
come (for example, quality-adjusted life 
years) relative to the incremental change 
in cost. The greater the ‘cost per quality-
adjusted life year’ or other eﬀectiveness 
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metric, the less desirable is the program. 
Performing this type of analysis requires 
knowledge of the BOI associated with 
each alternative. Here the question is how 
to best use resources in treating particular 
conditions. As an example, cost-eﬀective-
ness analysis demonstrated that vaccina-
tion against pneumococcal pneumonia 
could add a year of healthy life for adults 
age 65 and older at an additional cost of 
about US$1,000 per person.13 This ﬁnding 
supported Medicare coverage for the vac-
cination procedure, a signiﬁcant change in 
policy as Medicare had not previously paid 
for preventive services. Note that vaccina-
tion did not save money—program costs 
actually increased—but Congress viewed 
the gain in healthy years as a good value.
What does burden-of-illness analysis tell 
us about end-stage renal disease?
Studies on the burden of ESRD and related 
conditions such as chronic kidney disease 
are surprisingly few. However, from the 
United States Renal Data System we know 
that in 2004, some 472,000 ESRD patients 
accounted for $32 billion in direct medi-
cal costs.14 We can surmise that the bur-
den in terms of years of productive life 
lost, disability, and psychological distress 
is substantial.
What more could we learn from system-
atic analysis of the ESRD burden (Figure 1)? 
From a United States perspective, exam-
ining trends in BOI over time might 
improve understanding of the eﬀects of 
changes in case mix, medical technology, 
and hemodialysis facility infrastructure. 
Early in the program, Medicare coverage 
for renal replacement therapy was justi-
ﬁed as allowing beneﬁciaries to continue 
their employment. Patients would remain 
at least partially productive, thus oﬀsetting 
program costs. Over the years, case mix 
has changed, with increasing proportions 
of older patients and persons with diabe-
tes.15 What eﬀect has this had on the mix of 
direct and indirect costs and their magni-
tude over time? Technological intervention 
such as introduction of erythropoietin-
stimulating agents has largely eliminated 
severe anemia that impaired the survival 
and functional status of many patients. 
What has been the impact of erythropoi-
etin-stimulating agents on direct costs, 
productivity loss, and quality of life? Over 
the history of the Medicare ESRD program, 
the delivery system has shifted from hos-
pital-based, independent, not-for-proﬁt 
facilities to predominantly free-standing, 
chain-owned, for-proﬁt dialysis centers. 
Is this organizational evolution associ-
ated with change in either aggregate or per 
capita BOI?
As in the case of BOI analysis in general, 
perhaps the most fruitful application for 
this research is in cost-eﬀectiveness analy-
sis. The relentless increase in expendi-
tures for kidney disease as observed in the 
United States is on the horizon for other 
developed nations.16 Cost control will only 
be achieved with innovative approaches to 
prevention, early detection, and treatment 
of the causal factors leading to ESRD, as 
well as the long-term treatment of ESRD 
itself.17 BOI studies are needed as the 
foundation for cost-eﬀectiveness analysis 
of these potential programs.
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Figure 1 | A conceptual framework for the burden of illness of end-stage renal disease.  
New cases of end-stage renal disease (incidence) are characterized by patient socio-demographic 
and disease characteristics (case mix). Case mix and access to effective medical technology are 
determinants of mortality and therefore the prevalence of end-stage renal disease. While potentially 
reducing mortality and morbidity, advancing medical technology tends to increase direct costs 
of treatment. Morbidity, in combination with case mix and mortality, determines indirect costs 
attributable to lost productivity as well as the loss of quality-adjusted life years (QALYs).
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